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Objective: Superﬁcial Zone Protein (SZP) is expressed by the superﬁcial zone chondrocytes and is
involved in boundary lubrication of the articular cartilage surface. SZP protein expression is dependent
on anatomical location and is regulated by the transforming growth factor-b (TGF-b) pathway. The
hypothesis of this study was that between load-bearing, and non-load-bearing locations, of the femoral
medial condyle alternative splice isoforms of SZP are different, and regulated by TGF-b1.
Methods: Using reverse transcription-polymerase chain reaction (RT-PCR) we identiﬁed differentially
expressed SZP alternative splicing. Using recombinant proteins of the N-terminal region produced from
these isoforms, we identiﬁed differences in binding to heparin and the extracellular matrix.
Results:We identiﬁed a novel splice form of SZP (isoform E), lacking exons 2e5. Differences in alternative
splicing were observed between anterior load-bearing locations of the femoral medial condyle (M1)
compared to the posterior non-load-bearing location (M4). TGF-b1 increased splicing out of exons 4 and
5 encoding a heparin binding domain. The minimal induction time for changes in splicing by TGF-b1 at
the M1 location was 1 h, although this did change total SZP mRNA levels. Inhibition of Smad3 phos-
phorylation inhibited TGF-b1 induced splicing, and SZP protein expression. Recombinant proteins cor-
responding to isoforms upregulated by TGF-b1 had reduced binding. The SZP dimerization domain is
located within exon 3.
Conclusions: In conclusion, alternative splicing of SZP is regulated by TGF-b1 signaling and may regulate
SZP interaction with heparin/heparan sulfate or other components in the extracellular matrix of articular
cartilage by splicing out of the heparin binding domain.
 2010 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Articular cartilage is an avascular tissue with limited innate
potential for repair and regeneration. The tissue provides a low
friction surface for movements of the joints. Lubrication of these
surfaces is critical to normal function. Products of the proteoglycan 4
(prg4) gene1e5 have been identiﬁed as boundary lubricants of
articular cartilage and stress dissipaters within the synovial joint6.
These protein products have been named variously as lubricin, or
Superﬁcial Zone Protein (SZP). The function of SZP and lubricin
appears to be similar3, and these proteins are secreted by surface
zone chondrocytes and synovium1,7. As the tissue source used in this
manuscript derives from the superﬁcial zone of articular cartilage,
SZP will be used hereafter to refer to the product of the prg4 gene.o: A. Hari Reddi, Center for
acramento, CA 95817, United
.
Elsevier Ltd on behalf of OsteoartSZP plays a key role in the normal function of synovial joints. Loss of
function of SZP in human and mouse mutants displays precocious
joint pathology and osteoarthritis8. SZP is regulated in part by
cytokines involved in cartilage homeostasis1.
Bovine prg4 gene encodes SZP and has similar exon structure to
that of human, comprising 12 coding exons and a similar molecular
weight (approximately 345 kD). The full length bovine product is
1195 amino acids in length compared to that of human at 1404
amino acids. This difference is due to fewer mucin repeats within
exon 6, while the N- and C-terminal domains are highly homolo-
gous. Oligosaccharides attached to themucin repeats are thought to
be responsible for SZP’s lubricating ability as removal of the (1e3)
GaleGalNAc moieties by endo-N-acetyl-D-galactosaminidase
reduced lubricating activity by 77%9.
SZP protein expression varies across different anatomical loca-
tions of the bovine femoral condyles with locations of higher loading
having increased SZP expression10. This experimental model is
amenable to investigate the inﬂuence of chemical and physical forces
including mechanotransduction. Osteochondral plugs from the M1
(anterior medial and load bearing) and M4 (posterior medial andhritis Research Society International.
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These locations have shown the greatest variability of SZP expression
and mechanical loading10,11. Furthermore, upregulation of SZP
protein by shearwas through the transforming growth factor-b (TGF-
b) pathway10. ExogenousadditionofTGF-b1wassufﬁcient to alter the
SZP expression of tissue from non-load-bearing regions (M4) to
resemble that of load bearing tissue (M1)10. Thereforewe formulated
these hypotheses: (1) the greatest difference in splicing may exist
between the load bearingM1and non-load-bearingM4 locations, (2)
control of alternative splicing in articular cartilage between M1 and
M4 may be regulated by the TGF-b signaling pathway. We tested if
recombinant isoforms had functionally different binding abilities to
superﬁcial zonearticular cartilagematrix12. BecauseTGF-b splicesout
apotential heparin bindingdomain,wealso tested anddemonstrated
binding to heparin.Materials and methods
Materials
Articular cartilage was harvested from 1- to 3-week old bovine
stiﬂe (tibiofemoral) joints obtained from a local abattoir within 6 h
of sacriﬁce. Dulbecco Modiﬁed Eagle's Medium (DMEM)/F12 and
antibiotic solution (both from Invitrogen, Grand Island, NY), cell
culture components and reagents (from Sigma, St Louis, MO or
Fisher Scientiﬁc, Tustin, CA), and human recombinant TGF-b1,
Activin A, B and AB (R&D Systems Inc., Minneapolis, MN) were used
in this study. TGF-b1 Type 1 receptor inhibitor SB431542 and
cycloheximide were from Sigma, and TGF-b1 Type 1 receptor
inhibitor Type IV (Type IV), and Smad3 phosphorylation inhibitor
(SIS3) were from Calbiochem (San Diego, CA).Fig. 1. SZP alternative splicing varies by anatomical location. (A) Tissue was harvested from
femoral medial condyle10. (B) Alternative splicing of SZP in M1 and M4 (assembled from a
zone of articular cartilage.Tissue acquisition and culture
Bovine calf stiﬂe joints were opened using an aseptic technique,
and two side-by-side osteochondral explants were harvested from
M1 (anterior and load bearing) and M4 (posterior and non-load
bearing) regions of the femoral medial condyles [Fig. 1(A)]. Here-
after, these samples will be referred to as M1 and M4 explants. A
5 mm coring reamer was used to obtain the osteochondral explants
while an adjustable custom-made jig was used to trim the explants
to lengths of 4 mm removing the subchondral bone. The explants
were allowed to equilibrate in serum- and cytokine-free culture
medium consisting of DMEM/F12, 0.2% bovine serum albumin
(BSA), 1% penicillin/streptomycin, 50 mg/ml ascorbic acid 2-phos-
phate, and 5% CO2 at 37C for 24 h. The mediumwas replaced after
the equilibration period. Subsequently, the explants were incu-
bated in a medium supplemented with 10 ng/ml TGF-b1 or 5 mM
HCL with 0.1% BSA (vehicle control) for 1 and 2 days at 37C and 5%
CO2. Inhibitors (SB431542, Type IV, SIS3) or cycloheximide treated
samples were treated 1 h prior to addition of TGF-b1. All other wells
were treated with the vehicle control [1 ml/ml dimethyl sulfoxide
(DMSO) for SB431542, ethanol for Type IV, phosphate buffered
saline (PBS) for SIS3 and cycloheximide]. Following treatment the
top 200 mm was removed with a custom cutting jig and frozen in
liquid nitrogen for RNA extraction.Monolayer culture
Bovine calf stiﬂe joints were obtained from a local abattoir and
dissected under aseptic conditions. A Silvers miniature skin graft
knife (Integra, Plainsboro, NJ) was used to obtain superﬁcial zone
samples from locations M1 and M4 of approximately 200 mm.the anterior location M1 (load-bearing) and posterior M4 (non-load bearing) of the
single larger gel). (C) Five SZP isoforms (AeE) were identiﬁed in the bovine superﬁcial
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Indianapolis, IN) in culture medium containing 3% fetal bovine
serum (Gibco BRL, Grand Island, NY) for 3 h. Isolated chondrocytes
were plated as monolayers at a density of 2.5105 cells/well in
12-well culture plates (Corning, Corning, NY). Chondrocytes were
allowed to equilibrate and attach for 16 h in 10% serum containing
culture medium consisting of DMEM/F12, 0.2% BSA, 1% penicillin/
streptomycin, 50 mg/ml ascorbic acid 2-phosphate, and 5% CO2 at
37C. The mediumwas replaced after the equilibration period with
serum free DMEM/F12 and treated as described for explants11,13.
RNA extraction and RT-PCR
Total RNA was harvested from superﬁcial zone cartilage by
pulverizing samples using a metal impact chamber submerged in
liquid nitrogen. RNAextractionwas performed using theQiazol Lipid
RNeasy Kit (Qiagen, Valencia, CA). This utilizes a modiﬁed
phenoleguanidineechloroform extraction with on-membrane
DNase I digestion to avoid genomic DNA contamination. cDNA was
made from5 mg of total RNAusing Superscript First-Strand Synthesis
System with random hexamer primers (Invitrogen, Carlsbad, CA).
Primers were designed using Primer Express 1.9 (Applied Bio-
systems, Foster City, CA). Forward and reverse primers are:
50-AACAGCCATGGAGTGGAAAATACT-30 located in exon 1 and
50-AGTCCACTTCCATCTTCATCTATAACTG-30 located in exon 6, and
straddle the spliced exons. The PCR reactionwas optimized to ensure
all isoforms produced remained within the linear range during
ampliﬁcation. The following ampliﬁcation cycles were employed:
5 min at 95C followedby 30 cycles of 95C for 15 sec, 60C for 3 min,
72C for 3 min, and extension at 72C for 7 min. PCR products were
electrophoresed on 2% agarose gels for imaging and the bands were
excised and sequenced to identify the speciﬁc isoforms [Fig. 1(C)].
Real-time quantitative PCR was done in triplicate on the cDNA
with an ABI 7700 Sequence Detector and Sybr-Green reagents
(Applied Biosystems) following the recommended protocols using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)14 Forward
50-GGCGCCAAGAGGGTCAT-30, and Reverse 50-GTGGTTCACGCCCAT
CACA-30 and SZP Forward 50-AGAAAACCCGATGGCTATGA-30, Reverse
50-TCGCCCATCAGTCTAAGGAC-30 primers. Results were normalized
to GAPDH levels using the formula DCt (cycle threshold)¼ Ct of
GENE Ct of GAPDH. Total SZP was normalized to control and
treatment using DDCt calculated as DCt of TreatmentDCt Control.
Results are presented in the form of data points representing fold
change mean values one standard error of the mean.
As differences between isoforms A and C fall at or below the
2-fold detection limit for qRT-PCR15, isoform differences were
visualized using agarose gels. All samples were loaded at approxi-
mately equal amounts of GAPDH, which was determined using
GAPDH in a qRT-PCR reaction with an endpoint within the linear
range. Total amount of DNA per gel was within the linear range of
the agarose gel (w300e900 ng). Gels were analyzed for densi-
tometry in ImageJ (NIH, Bethesda, MD) isoforms were normalized
as a percentage of total SZP. Similar methods for imaging splice
forms have been used before16.
Immunoblot analysis
Equal volumes of supernatant from monolayer cultures were
analyzed for secreted SZP17, on 3% stacking, 5% resolving sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
gels and transferred onto Immun-Blot PVDF Membrane (Bio-Rad,
Hercules, CA). Monoclonal antibody against SZP, S6.7918
(a generous gift from Dr. T. Schmid, Rush Medical College,
Chicago, IL), followed by horseradish peroxidase (HRP) -conjugated
goat anti-mouse IgG (Bio-Rad). Immunoblots were visualized withSupersignal West Pico chemiluminescence reagents (Thermo-
Scientiﬁc, Waltham, MA). Immunoblot analysis of recombinant SZP
isoforms was performed on 293Awhole cell lysates. Equal amounts
of total protein of samples were separated by reducing and non-
reducing electrophoresis in 15% precast gels (Bio-Rad). Immuno-
blotswere treated as previously describedwith the exception of the
use of monoclonal anti-V5 antibody (Invitrogen).
Recombinant SZP isoforms
Recombinant truncated eGFP fusion proteins were produced
encoding the last amino acids of exon 1 (QQASS) through the
chondroitin sulfate attachment site at the beginning of exon 6 from
each of the splice forms identiﬁed. In brief, these were cloned into
a C-terminal egfp-c2 plasmid (Invitrogen) and a V5 tagwas attached
to the N-terminal end. A sixth clone representing empty green ﬂu-
oroscence protein (GFP) vector was also used as a negative control.
Plasmids were transfected using Lipofectamine 2000 (Invitrogen)
into human embryonic kidney (HEK) 293A cells. After 48 h cell
lysate was harvested.
Recombinant binding ELISA
An enzyme-linked immunosorbent assay (ELISA)was performed
to determine if different isoforms bind differently to the superﬁcial
zone extracellular matrix. Superﬁcial zone articular cartilage was
removed from load-bearing regions of the lateral condyle of bovine
stiﬂe joints, frozen in liquid nitrogen and then pulverized while
frozen. Extracellularmatrixwas extractedwith 4 MguanidineeHCl,
0.05 M sodium carbonate pH 7.4 solution containing phenyl methyl
sulfonyl ﬂuoride (PMSF) and protease inhibitor cocktail (Sigma)
overnight at 4 C. After extraction the solution was spun down to
remove insoluble components. Extracted superﬁcial zone extracel-
lular matrix (10.0 mg/ml) or sodium heparin (2.0 mg/ml) was diluted
in 0.05 M sodium carbonate and incubated overnight at 4 C in
Maxisorp black well plates (Thermo Fisher Scientiﬁc). Extracellular
matrix adsorbed plates were blocked for 1 h at room temperature
with 1%BSAandwashed. Recombinant truncated SZP isoformswere
serially diluted in PBS and applied to ELISA plates for 1 h. Isoform
binding was visualized using 1:5000 mouse anti-v5 primary anti-
body (Invitrogen), and 1:3000 goat anti-mouse HRP-linked
secondary antibody (Bio-Rad). Signal was visualized using Super-
Signal West Femto Chemiluminescence Substrate (Thermo Scien-
tiﬁc). ELISA signal was normalized to equivalent amounts of protein
run on immunoblot and analyzed for densitometry in ImageJ.
Statistical analysis
Differences inSZPmRNAexpression followingcytokine treatment
were evaluated using a paired t-test (EXCEL Microsoft, Redmond,
WA). A signiﬁcance level of P< 0.05 was used to determine differ-
ences between groups, based on values from the gel densitometry.
Results
SZP alternative splicing varies by anatomical location
We mapped the alternative splice forms by anatomical location
based on the previously identiﬁed mapping scheme [Fig. 1(A)]
between the anterior load bearing M1 and posterior non-load-
bearing region M410. SZP isoform ratios differed between the M1
and M4 locations in freshly isolated tissue [Fig. 1(B)]. There are ﬁve
splice forms all in-frame for exons 2 through 5. The SZP isoforms
identiﬁed in the superﬁcial zone of articular cartilage (AeE) are
listed in Fig. 1C. Isoform E lacking exons 2e5 was novel. In the M1
Fig. 2. Response to TGF-b1 differs between explants from load and non-load bearing
for splicing out of exons 4 and 5 and total SZP mRNA expression. (A) 24 and 48 h M1
and M4 explant cultures treated with 10 ng/ml TGF-b1. (B) Total SZP was signiﬁcantly
(P¼ 0.007) upregulated at (5.11.3 fold) 24 h (a) and (9.51.8 fold) 48 h (b)
(P¼ 0.011) in M1 explants but not until (P¼ 0.044) 48 h (c) (3.9 1.4 fold) in M4
explants (error bars represent 95% conﬁdence interval, n¼ 6, 9, 7, and 3 for 1 h, 4 h,
24 h and 48 h timepoints respectively).
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compared to isoformA (containing exons 1e5). This was designated
as “full length” as this band is derived from an mRNA containing all
of the exons in the alternatively spliced region and therefore all of
the coding exons 1e12. This was reversed in M4 (n¼ 7).SZP alternative splicing is altered by TGF-b1
To investigate whether TGF-b1 regulated alternative splicing of
SZP we treated explant cultures for 24 and 48 h with 10 ng/ml TGF-
b1. TGF-b1 was able to increase isoform C and decrease the full
length isoform A in M1 and M4 explant tissues [Fig. 2(A)] with 24 h
of treatment (n¼ 7). Temporal differences in total SZP were also
observed between the M1 and M4 locations by qRT-PCR. Explants
from M1 upregulated total SZP mRNA faster then M4 explants
[Fig. 2(B)]. A signiﬁcant increase in total SZP mRNA was seen by
24 h (5.071.3 fold n¼ 7) and 48 h (9.51.8 fold n¼ 3) in M1
explants (P¼ 0.007, 0.011). A signiﬁcant increase (3.91.4 fold) in
SZP mRNA was not observed in M4 explants until 48 h after treat-
ment (P¼ 0.044). Signiﬁcant differences were observed between
24 h timepoints of M1 and M4 explants (P¼ 0.036), but not 48 h
timepoints (P¼ 0.26). To determine the minimal induction time ofFig. 3. TGF-b1 induces splicing out of exons 4 and 5 in SZP within 1 h and does not require
10 ng/ml TGF-b1. (B) 1 h M1 explants treated with 10 ng/ml TGF-b1 were pretreated for 1this effect, explants and monolayer cultures were treated for 1 h
with 10 ng/ml TGF-b1. Total levels of SZP did not change at 1 h post-
treatment in either M1 or M4 explants [Fig. 2(B)]. An increase in
isoform C (P¼ 0.004) was observed at 1 h post-treatment with TGF-
b1 at the M1 location [Fig. 3(A)] and a decrease in the full length
isoform A (P¼ 0.001) was also observed (n¼ 6), indicating the M1
location is more sensitive to TGF-b1 at 1 h than the M4 location.
Addition of 40 mM cycloheximide did not affect the increase in
isoform C by addition of TGF-b1 after 1 h (n¼ 3) in M1 explants
(P¼ 0.74). [Fig. 3(B)] This demonstrates de-novo protein synthesis is
not needed for upregulation of isoform C in explants.SZP splicing is mediated through the TGF-b Type 1 receptor kinase
and Smad3
An inhibitor of TGF-b1 Type 1 receptor kinase (SB431542) was
used to determine if this splicing signal was transduced through the
TGF-b Type 1 receptor. Although 10 mMSB431542was able to inhibit
a decrease in isoform A by TGF-b1 after 1 h (n¼ 4) in M1 explants
[Fig. 4(A)], the increase in isoformC by TGF-b1 onlywasweak, likely
due to the use of DMSO as a vehicle control. Therefore this was
repeated in 48 h monolayer culture, where addition of 10 mM
SB431542was able to inhibit the increase in isoform C and decrease
in isoformAby TGF-b1 (P¼ 0.009, n¼ 3) [Fig. 4(B)]. This ﬁndingwas
then also conﬁrmed in 48 h (P¼ 0.019, n¼ 3) monolayer cultures
with 1 mM of Type IV inhibitor (Calbiochem)19, a different TGF-
b receptor Type I kinase inhibitor, with similar results [Fig. 4(C)].
As Smad3 is one of the downstream targets of the TGF-b Type 1
receptor, we inquired whether Smad3 phosphorylation was
required for splicing. Therefore 10 mM of SIS3 (Calbiochem)20
a speciﬁc inhibitor of Smad3 phosphorylation, was used. Addition
of 10 mM SIS3 was sufﬁcient to inhibit upregulation of isoform C in
1 h (n¼ 3) treatment of explants by TGF-b1 [Fig. 4(D)] (P¼ 0.006),
and 48 h (n¼ 3) monolayer [Fig. 4(E) right] (P¼ 0.005). Further-
more, SIS3 was able to downregulate total SZP protein secreted into
the media (n¼ 3) [Fig. 4(F)]. Addition of SIS3 downregulated both
endogenous levels of SZP protein and that stimulated by TGF-b1.
Differences in total SZP secreted into the media were also observed
between M1 and M4 monolayer cultures although both upregu-
lated SZP protein in response to TGF-b1 treatment.Exons 4 and 5 increase superﬁcial zone articular cartilage
extracellular matrix binding
To identify differences in matrix binding between isoforms,
truncated recombinant isoforms of SZP were produced [Fig. 5(A)].
Recombinant truncated isoforms of SZP bound strongest to extra-
cellular matrix components present in guanidine extracts of super-
ﬁcial zone articular cartilage when exons 4 and 5 were present.
Binding of isoform A (exons 2e5) and isoform B (exons 3e5) wasnew protein synthesis in explant tissue. (A) 1 h M1 and M4 explants were treated with
h with 40 mM cycloheximide.
Fig. 4. Inhibition of the Type 1 receptor, or Smad3, phosphorylation blocks TGF-b1 regulated splicing out of exons 4 and 5. (A) 1 h M1 explants treated with 10 ng/ml TGF-b1 were
pretreated for 1 h with 10 mM SB431542 a TGF-b Type 1 receptor inhibitor. (B and C) 48 h monolayer culture treated with 10 ng/ml TGF-b1 were pretreated for 1 h with 10 mM
SB431542, or 1 mM Type IV inhibitor (a distinct TGF-b Type 1 receptor inhibitor). (D) 1 h M1 explant or 48 h M1 monolayer cultures (E) treated with 10 ng/ml TGF-b1 were
pretreated for 1 h with 10 mM SIS3, a Smad3 phosphorylation inhibitor. (C) SDS-PAGE immunoblot of SZP from 24 and 48 h TGF-b1 treated M1 and M4 superﬁcial zone chondrocyte
monolayers pretreated for 1 h with 10 mM SIS3.
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which had weaker binding observed [Fig. 5(B)]. Levels of binding of
isoforms C and D were similar to that of isoform E, which contained
only a partial exon 6 and the C-terminus. The level of signal at the no
isoform control is similar to isoforms CeE at all concentrations.
Therefore this represents background signal and indicates a lack of
binding for isoforms CeE. As exon 4 encodes a heparin binding
domain, we also tested if this was competent to bind to sodiumheparin. Binding of isoforms A, B with exons 4 and 5 present was
strongest, with weaker binding of forms lacking exons 4 and 5 (CeE)
[Fig. 5(B)].
Exon 3 is a potential dimerization domain
SZP has been reported to exist in both monomeric and dimeric
forms12,21 through a disulﬁde bondwithin the N-terminal domains.
Fig. 5. Splicing out of exons 4 and 5 encoding the heparin binding domain reduces matrix and heparin binding of recombinant N-terminal SZP. (A) Recombinant GFP-constructs
incorporating a V5 tag were produced of the N-terminal of each of the alternative splice isoforms of SZP identiﬁed in superﬁcial zone articular cartilage. (B) Binding of recombinant
isoforms (A and B) containing exons 4 and 5 (a heparin binding domain) to guanidine extracted superﬁcial zone cartilage matrix was stronger than forms lacking exons 4 and 5
(Ce E) (n¼ 4, error bars represent 95% conﬁdence interval). Forms A, and B containing the heparin binding domain also showed increased binding to sodium heparin over forms
lacking exons 4 and 5 (CeE) (n¼ 4, error bars represent 95% conﬁdence interval). (C) Non-reducing (right) and reducing (left) SDS-PAGE immunoblots of recombinant isoforms
demonstrated dimers (arrow) for all forms containing exon 3 (AeD), but not for isoform E which lacks exon 3.
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truncated SZP isoforms were run on SDS-PAGE under reducing and
non-reducing conditions. Bands of the correct size for dimers were
observed for all forms except E (corresponding to isoform E), which
lacks exons 2 through 5 [Fig. 5(C) left]. No dimers were observed on
the reducing gel [Fig. 5(C) right]. Isoform D which only contains
exon 3 (but not 2, 4, or 5) had a band of the correct size for a dimer.
This supports exon 3, one of two repeated Somatomedin B domains,
being sufﬁcient for dimerization of SZP.
Discussion
Alternative splicing of RNA permits the production of distinct
protein isoforms from a single gene. Several splice forms of SZP
have been identiﬁed in normal cartilage involving exons 2, 4, and
51,22. SZP alternative splicing in tendon has been shown to vary
based on anatomical location corresponding to load23. Shear
loading induced upregulation of SZP protein through the TGF-
b Type 1 receptor kinase10. Previous work has demonstrated SZPprotein expression increases with dynamic loading, and that this
alters the ratio of the protein product sizes found when compared
to unloaded controls24.
It is noteworthy that alternative splicing of RNA in cartilage
explant cultures is different in the various anatomical sites such as
load bearing M1 compared to the non-load-bearing M4 site. In the
M1 site splicing out of exons 4 and 5 is upregulated. Treatment of
the non-load-bearing site M4 explant with TGF-b1 alters the
alternative splicing to resemble load bearing M1.
The rapidity of the splicing response (1 h treatment) to TGF-b1
treatment in the absence of protein synthesis in cartilage explant
cultures is remarkable. Inhibition of Smad3 phosphorylation
demonstrates that phosphorylation of Smad2 is not sufﬁcient to
regulate splicing out of exons 4 and 5 in 1 h M1 explants or 48 h
monolayer culture. However, this action could be indirect due to
blocking of TGF-b induced upregulation of TGF-b signaling25e27.
Disulﬁde bonded dimerization of SZP has been identiﬁed to occur
within the N-terminal region of themolecule12, localized to a region
of exons 2 through 5. Although not deﬁnitive, the presence of dimers
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Somatomedin B domain encoded within exon 3 as being the likely
dimerization domain, it remains possible that exon 2which contains
a similar Somatomedin B domain is also capable of dimerizing. This
remains unlikely to exist in nature though, as exon 3 is present in all
alternative splice forms identiﬁed except E, and no isoforms were
identiﬁed containing exon 2 but not 3. Loss of exon 3 appears to be
relatively rare, as isoform E appeared to be of low abundance.
The functional differences between the alternatively spliced RNA
forms are critical. The SZP C-terminal domain is critical for binding
to extracellular matrix21,28 and recently a model supporting
N-terminal domain binding abilities has been described12,29.
Although the binding conditions are quite different, this is puzzling
in the light of, previous recombinant work21,28 which showed
minimal binding of the N-terminal domain in recombinant proteins
to intact cartilage superﬁcial zone. Recent work has proposed that
SZP may exist as a horseshoe conﬁguration with both N and C
terminals bound to the extracellular matrix, leaving the highly
glycosylated central mucin domain exposed for interactions during
boundary lubrication12. Here we investigated the role of the N-
terminal domains to bind matrix components, as potentially
modulated by splicing. Compared to the isoforms containing exons
4 and 5 (A and B), those isoforms lacking exons 4 and 5 resulted in
reduced matrix or heparin binding. However, as these matrix
components were guanidine extracted, this may not represent
native tissue conditions. This does suggest that SZP lacking exons 4
and 5, as upregulated by TGF-b, may have different binding
capabilities.
Splicing may serve as a mechanism to control the ratio of SZP
bound to the articular cartilage compared to SZP free ﬂoating in the
synovial ﬂuid, which can have consequences on lubrication30.
Therefore, in vivo conditions (changes in biochemical homeostasis
or mechanical loading) might change binding ability of SZP to
matrix, and subsequently lubrication of the joint. Furthermore,
mechanistically this suggests that Smad3 may regulate both SZP
protein concentration and the speciﬁc isoform produced through
alternative splicing. Growth factor regulation of splicing, especially
that of quick changes in splicing due to phosphorylation of factors
controlling splicing has been described in other systems31.
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